OPGN: AI 评分 63/100 — AI 分析 (4月 2026)

OpGen, Inc. is a precision medicine company focused on developing and commercializing molecular microbiology solutions. Their products aid in combating infectious diseases and antimicrobial resistance.

Key Facts: AI Score: 63/100 Sector: Healthcare

公司概况

概要：

OpGen, Inc. specializes in molecular microbiology solutions, offering diagnostic tools like the Acuitas AMR Gene Panel and Unyvero Platform. These technologies assist clinicians in identifying pathogens and antimicrobial resistance, contributing to improved patient outcomes and infection control within the healthcare sector. The company operates in the United States and internationally.

OPGN是做什么的？

OpGen, Inc., established in 2001 and headquartered in Rockville, Maryland, is a precision medicine company dedicated to developing and commercializing molecular microbiology solutions. The company's mission is to combat infectious diseases by providing clinicians with advanced diagnostic tools and information to enhance patient outcomes and reduce the spread of multidrug-resistant microorganisms. OpGen's product portfolio includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed for the detection and identification of bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies. This technology enables rapid and accurate identification of resistance genes, aiding in the selection of appropriate antibiotic therapies. Additionally, OpGen offers Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The ARES Technology Platform is another key offering, featuring a comprehensive reference database on antimicrobial resistance using next-generation sequencing technology and artificial intelligence-powered bioinformatics solutions for antibiotic response prediction. The Unyvero Platform, an automated sample-to-answer molecular diagnostics platform, integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and antibiotic resistance markers. OpGen collaborates with the New York State Department of Health and ILÚM Health Solutions, LLC, to develop a research program focused on detecting, tracking, and managing antimicrobial-resistant infections within healthcare institutions.

OPGN的投资论点是什么？

OpGen, Inc. presents a notable market position within the precision medicine and molecular diagnostics space. The company's focus on combating antimicrobial resistance (AMR) aligns with a growing global health concern. Key value drivers include the increasing adoption of OpGen's Acuitas AMR Gene Panel and Unyvero Platform, driven by the need for rapid and accurate detection of AMR genes and pathogens. The collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, provides a platform for further research and development in antimicrobial resistance management. However, potential risks include competition from established players in the diagnostics market and the need for continued innovation to maintain a competitive edge. With a market capitalization of $0.25 billion and a profit margin of 76.0%, OpGen demonstrates financial stability and growth potential.

OPGN在哪个行业运营？

OpGen operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in molecular biology and the increasing prevalence of infectious diseases. The market for antimicrobial resistance (AMR) diagnostics is expanding due to the urgent need for rapid and accurate detection of resistant pathogens. Competition includes established diagnostic companies and emerging players offering innovative solutions. OpGen's focus on precision medicine and its comprehensive product portfolio position it to capitalize on the growing demand for advanced diagnostic tools in healthcare.

Medical - Diagnostics & Research

Healthcare

OPGN有哪些增长机遇？

Expansion of Acuitas AMR Gene Panel adoption: The increasing global threat of antimicrobial resistance (AMR) drives the demand for rapid and accurate diagnostic tools. OpGen's Acuitas AMR Gene Panel offers a solution for detecting and identifying bacterial nucleic acids and genetic determinants of AMR. The market for AMR diagnostics is projected to reach $4.5 billion by 2028, presenting a significant growth opportunity for OpGen. Timeline: Ongoing.
Leveraging the ARES Technology Platform: OpGen's ARES Technology Platform, with its comprehensive reference database and AI-powered bioinformatics, provides a competitive advantage in antibiotic response prediction. The platform can be expanded to include additional pathogens and resistance genes, broadening its applicability and market reach. The market for AI in drug discovery is expected to reach $2 billion by 2027. Timeline: Ongoing.
Strategic collaborations and partnerships: Collaborating with healthcare institutions and research organizations can accelerate the development and commercialization of OpGen's diagnostic solutions. The ongoing collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, serves as a model for future partnerships. Such collaborations can provide access to valuable data, expertise, and funding. Timeline: Ongoing.
Geographic expansion into international markets: OpGen has the opportunity to expand its market presence beyond the United States by targeting international markets with a high prevalence of infectious diseases and AMR. This expansion can be achieved through strategic partnerships, distribution agreements, and direct sales efforts. The global market for molecular diagnostics is projected to reach $14 billion by 2025. Timeline: 2027-2030.
Development of novel diagnostic assays: Investing in research and development to create new diagnostic assays for emerging infectious diseases and antimicrobial resistance mechanisms can drive future growth. This includes exploring new technologies such as next-generation sequencing and CRISPR-based diagnostics. The market for novel diagnostic assays is constantly evolving, offering opportunities for innovation and market leadership. Timeline: 2028-2032.

Market capitalization of $0.25 billion indicates the company's current valuation in the market.
A P/E ratio of 36.43 suggests investors are willing to pay a premium for each dollar of earnings, reflecting growth expectations.
Profit margin of 76.0% demonstrates strong profitability and efficient operations.
Gross margin of 98.9% indicates effective cost management in the production of diagnostic solutions.
Beta of -1.93 suggests the stock price moves inversely to the market, potentially offering diversification benefits.

OPGN提供哪些产品和服务？

Develop and commercialize molecular microbiology solutions.
Offer the Acuitas AMR Gene Panel for detecting antimicrobial resistance.
Provide Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Utilize the ARES Technology Platform for antibiotic response prediction.
Offer the Unyvero Platform for automated molecular diagnostics.
Help clinicians with information about life-threatening infections.
Decrease the spread of infections caused by multidrug-resistant microorganisms.

OPGN如何赚钱？

Sales of diagnostic kits and platforms (Acuitas AMR Gene Panel, Unyvero Platform).
Licensing of ARES Technology Platform and related intellectual property.
Collaborative research and development agreements with healthcare institutions.
Service contracts for maintenance and support of diagnostic equipment.

Hospitals and healthcare systems.
Clinical microbiology laboratories.
Research institutions and universities.
Public health organizations.

Proprietary ARES Technology Platform with extensive antimicrobial resistance database.
Established relationships with key healthcare institutions and research organizations.
Unyvero platform provides a comprehensive solution for molecular diagnostics.
Expertise in molecular microbiology and infectious disease diagnostics.

什么因素可能推动OPGN股价上涨？

Ongoing: Increasing adoption of Acuitas AMR Gene Panel due to rising antimicrobial resistance.
Ongoing: Expansion of ARES Technology Platform capabilities and database.
Upcoming: Potential new partnerships with healthcare institutions for research and development.
Upcoming: Possible expansion into new international markets.
Ongoing: Continued development of novel diagnostic assays for emerging infectious diseases.

OPGN的主要风险是什么？

Potential: Competition from established diagnostic companies with greater resources.
Potential: Regulatory changes affecting the approval and reimbursement of diagnostic tests.
Potential: Technological advancements rendering existing products obsolete.
Ongoing: Limited market presence compared to larger competitors.
Ongoing: OTC market listing may limit access to capital and investor confidence.

OPGN的核心优势是什么？

Proprietary ARES Technology Platform for antimicrobial resistance prediction.
Comprehensive Unyvero Platform for automated molecular diagnostics.
Collaboration with New York State Department of Health and ILÚM Health Solutions, LLC.
Strong gross margin of 98.9%.

OPGN的劣势是什么？

Limited market presence compared to larger diagnostic companies.
Reliance on a small number of key products.
OTC market listing may limit access to capital.
Beta of -1.93 indicates high volatility.

OPGN有哪些机遇？

Expansion of Acuitas AMR Gene Panel adoption in response to increasing antimicrobial resistance.
Geographic expansion into international markets.
Development of novel diagnostic assays for emerging infectious diseases.
Strategic partnerships with healthcare institutions and research organizations.

OPGN面临哪些威胁？

Competition from established diagnostic companies.
Regulatory changes affecting the approval and reimbursement of diagnostic tests.
Technological advancements rendering existing products obsolete.
Economic downturn impacting healthcare spending.

OPGN的竞争对手是谁？

Andina Acquisition Corp. III — Focuses on special purpose acquisition rather than diagnostics. — (ANPCF)
Bloom Health Partners Inc. — Offers occupational health and safety solutions. — (BLMH)
Confident Cannabis Inc. — Provides software solutions for the cannabis industry. — (CNFHF)
Integrated DNA Technologies Inc — Develops and manufactures products for genomics applications. — (INTI)
LianBio — Focuses on developing and commercializing pharmaceutical products. — (LIANY)

Key Metrics

MoonshotScore: 63/100

Company Profile

CEO: Christian-Laurent Benoit Bonte
Headquarters: Rockville, US
Employees: 85
Founded: 2015

AI Insight

AI analysis pending for OPGN

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does OpGen, Inc. do?

OpGen, Inc. is a precision medicine company that develops and commercializes molecular microbiology solutions. The company's products, including the Acuitas AMR Gene Panel and Unyvero Platform, are designed to help clinicians rapidly and accurately identify pathogens and antimicrobial resistance genes. By providing this critical information, OpGen aims to improve patient outcomes, reduce the spread of infections, and combat the growing threat of antimicrobial resistance. The company operates in the United States and internationally, serving hospitals, clinical laboratories, and research institutions.

What do analysts say about OPGN stock?

AI analysis is pending for OPGN stock. Generally, analyst opinions on diagnostic companies like OpGen consider factors such as revenue growth, product pipeline, market share, and regulatory approvals. Key valuation metrics include price-to-earnings ratio, price-to-sales ratio, and discounted cash flow analysis. Growth considerations involve the company's ability to expand its product offerings, enter new markets, and maintain a competitive edge in the rapidly evolving diagnostics industry. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

What are the main risks for OPGN?

OpGen, Inc. faces several risks inherent to the medical diagnostics industry. These include competition from larger, more established companies, regulatory hurdles in obtaining approvals for new products, and the potential for technological obsolescence. The company's reliance on a limited number of key products also poses a risk, as does its listing on the OTC market, which may limit access to capital and investor confidence. Additionally, the company is subject to risks related to intellectual property protection and potential product liability claims. Investors should carefully consider these risks before investing in OPGN.